THE PROBLEM
Protein misfolding diseases are associated with protein aggregation, oxidative stress and associated inflammatory responses, believed to be critical mediators of cell death. Protein misfolding is involved in more than fifty medical disorders, including several neurodegenerative and skeletal muscle diseases. Novel approaches that selectively attenuate oxidative stress and inflammation in diseased tissue have the potential to provide benefit to millions of patients which currently have few or no beneficial treatment options.
PARAMAG'S INNOVATIVE APPROACH
The foundation of ParaMag Biosciences' technology is based upon years of research by Dr. John Voss at the University of California, Davis, focusing on a "spin label" chemistry platform. Dr. Voss' laboratory has engineered a series of proprietary spin labeled naturally occurring antioxidants that selectively bind to amyloid and provide neuronal protection from toxic effects of amyloid-beta. These molecules have been termed paramagnetic amyloid ligands (PALs) as they are not only neuroprotective but also able to be visualized in the brain with Magnetic Resonance Imaging.
OUR FOCUS
Therapy: The core competency of this UC Davis spin-out company lies in the design and development of novel, paramagnetic catalytic antioxidants that can enter cells and prevent the toxic event of protein misfolding.
Diagnostics: Our theranostic paradigm using PALs unites diagnostic and therapeutic applications allowing for a single agent to diagnose, monitor, and treat the disease. These theranostic agents provide a transition from conventional medicine to a contemporary personalized and precise approach.
Management
John Voss, Ph.D.
Brian Rogers, Ph.D., MBA
Brian Rogers, Ph.D., MBA
Dr. Voss , Founder and President, is a professor in the Department of Biochemistry and Molecular Medicine in the Medical School at UC Davis and Chair of the UC Davis Graduate Program of Biophysics. He is a renowned expert in using biophysical methods to study the structural basis for Alzheimer’s Disease. In addition, Dr. Voss has over 20 years of experience using EPR spectroscopy to study the of biochemistry radicals and spin labels. His research at the University of California, Davis has been related to the study of protein biophysics and to oxidative stress and the modulation of pathogenic protein and peptide conformations. He is the inventor of the platform for our small molecules that bind intra-cellular Alzheimer’s pathology.
Brian Rogers, Ph.D., MBA
Brian Rogers, Ph.D., MBA
Brian Rogers, Ph.D., MBA
Dr. Rogers, Founder and Chief Development Officer, is a Board Certified Toxicologist and entrepreneur with extensive experience in preclinical drug development. He has been involved many start-up biotechnology companies and has experience in the design and implementation of numerous preclinical development plans that have culminated in well over 100 INDs and over 20 NDAs, several indicated for neurological disease. He is also co-founder and CEO of Pacific BioDevelopment, LLC, his own preclinical consulting firm, serving the biotechnology community for over 20 years.
Sandra Reynoso, Ph.D., MBA
Brian Rogers, Ph.D., MBA
Sandra Reynoso, Ph.D., MBA
Dr. Reynoso, Founder and Chief Operating Officer, is an entrepreneur and trained immunologist with 10 years of drug development experience at Genentech, Syntex and Arris Pharmaceuticals. She has been involved in several startups and has significant experience in operations and business development. She is very familiar with the drug development process and has worked with contract research organizations extensively.
New Data
